Renovaro Appoints Nathen Fuentes as Chief Financial Officer
Renovaro (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, has appointed Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh.
Fuentes brings extensive experience in biotechnology and specialty healthcare finance, with expertise in leading acquisition and organic growth initiatives. His previous roles include CFO positions at Telomir Pharmaceuticals, Emergence Health Holdings, Divergent Dental Group, Family First Homecare, and Dermatology Medical Partners. He also served as Controller at Glytec and worked at PricewaterhouseCoopers.
The new CFO holds a Bachelor of Science in marketing from the University of Florida and a Master of Science in accounting from Fairfield University. His appointment aims to support Renovaro's mission of revolutionizing healthcare through advanced cancer diagnostics and personalized immunotherapy solutions.
Renovaro (NASDAQ: RENB), un pioniere nella diagnostica e nelle terapie per il cancro alimentato dall'intelligenza artificiale, ha nominato Nathen Fuentes, CPA, come Direttore Finanziario a partire dal 2 gennaio 2025, sostituendo il CFO ad interim Simon Tarsh.
Fuentes porta con sé un'ampia esperienza nella biotecnologia e nella finanza del settore sanitario specializzato, con competenze nella guida di iniziative di acquisizione e crescita organica. Le sue precedenti posizioni includono ruoli come CFO presso Telomir Pharmaceuticals, Emergence Health Holdings, Divergent Dental Group, Family First Homecare e Dermatology Medical Partners. Ha anche ricoperto il ruolo di Controller presso Glytec e ha lavorato in PricewaterhouseCoopers.
Il nuovo CFO ha conseguito una laurea in marketing presso l'Università della Florida e un master in contabilità presso la Fairfield University. La sua nomina mira a supportare la missione di Renovaro di rivoluzionare l'assistenza sanitaria attraverso diagnosi avanzate per il cancro e soluzioni di immunoterapia personalizzate.
Renovaro (NASDAQ: RENB), un pionero en diagnósticos y terapias para el cáncer impulsados por inteligencia artificial, ha nombrado a Nathen Fuentes, CPA, como Director Financiero a partir del 2 de enero de 2025, reemplazando al CFO interino Simon Tarsh.
Fuentes aporta una amplia experiencia en biotecnología y finanzas de atención médica especializada, con conocimientos en la dirección de iniciativas de adquisición y crecimiento orgánico. Sus roles anteriores incluyen posiciones de CFO en Telomir Pharmaceuticals, Emergence Health Holdings, Divergent Dental Group, Family First Homecare y Dermatology Medical Partners. También se desempeñó como Controller en Glytec y trabajó en PricewaterhouseCoopers.
El nuevo CFO posee una licenciatura en marketing de la Universidad de Florida y una maestría en contabilidad de la Universidad de Fairfield. Su nombramiento tiene como objetivo apoyar la misión de Renovaro de revolucionar la atención médica a través de diagnósticos avanzados de cáncer y soluciones de inmunoterapia personalizadas.
레노바로 (NASDAQ: RENB)는 인공지능을 기반으로 한 암 진단 및 치료의 선도 기업으로, 네이든 푸엔테스 CPA를 2025년 1월 2일부로 최고재무책임자(CFO)로 임명하였으며, 임시 CFO인 사이먼 타시를 대체하게 됩니다.
푸엔테스는 생명공학 및 전문 의료 재무 분야에서 광범위한 경험을 가지고 있으며, 인수 및 유기적 성장 이니셔티브를 이끌어 온 전문성을 지니고 있습니다. 그의 이전 직무는 텔로미르 제약사, 이머전스 헬스 홀딩스, 다이버젠트 덴탈 그룹, 패밀리 퍼스트 홈케어, 피부과 의료 파트너스의 CFO를 포함합니다. 그는 또한 글리텍에서 컨트롤러로 근무하였고, 프라이스워터하우스쿠퍼스에서 일했습니다.
새로운 CFO는 플로리다 대학교에서 마케팅 학사 학위를, 페어필드 대학교에서 회계 석사 학위를 취득했습니다. 그의 임명은 고급 암 진단 및 개인 맞춤형 면역 요법 솔루션을 통해 의료 혁신을 지원하는 레노바로의 사명을 지원하는 것을 목표로 합니다.
Renovaro (NASDAQ: RENB), un pionnier dans le diagnostic et la thérapie du cancer alimenté par l'intelligence artificielle, a nommé Nathen Fuentes, CPA, au poste de directeur financier à compter du 2 janvier 2025, remplaçant le directeur financier par intérim Simon Tarsh.
Fuentes apporte une vaste expérience dans la finance des biotechnologies et des soins de santé spécialisés, avec une expertise dans la direction d'initiatives d'acquisition et de croissance organique. Ses précédents postes incluent des fonctions de directeur financier chez Telomir Pharmaceuticals, Emergence Health Holdings, Divergent Dental Group, Family First Homecare et Dermatology Medical Partners. Il a également été contrôleur chez Glytec et a travaillé chez PricewaterhouseCoopers.
Le nouveau directeur financier détient un Bachelor of Science en marketing de l'Université de Floride et un Master of Science en comptabilité de l'Université de Fairfield. Sa nomination vise à soutenir la mission de Renovaro de révolutionner les soins de santé grâce à des diagnostics avancés du cancer et des solutions d'immunothérapie personnalisées.
Renovaro (NASDAQ: RENB), ein Pionier in der Krebsdiagnostik und -therapie, die durch künstliche Intelligenz unterstützt wird, hat Nathen Fuentes, CPA, zum Chief Financial Officer ernannt, der am 2. Januar 2025 in Kraft tritt und den interimistischen CFO Simon Tarsh ersetzt.
Fuentes bringt umfangreiche Erfahrungen in der Biotechnologie und im Finanzwesen des spezialisierten Gesundheitssektors mit, insbesondere in der Führung von Akquisitions- und organischen Wachstumsinitiativen. Zu seinen vorherigen Positionen gehören CFO-Posten bei Telomir Pharmaceuticals, Emergence Health Holdings, Divergent Dental Group, Family First Homecare und Dermatology Medical Partners. Er war auch Controller bei Glytec und arbeitete bei PricewaterhouseCoopers.
Der neue CFO hat einen Bachelor of Science in Marketing von der University of Florida und einen Master of Science in Buchhaltung von der Fairfield University. Seine Ernennung zielt darauf ab, Renovaros Mission zu unterstützen, das Gesundheitswesen durch fortschrittliche Krebsdiagnose und personalisierte Immuntherapielösungen zu revolutionieren.
- Appointment of experienced CFO with specific biotechnology and healthcare industry expertise
- Strong track record in managing acquisitions and organic growth initiatives
- Extensive experience in financial leadership roles within healthcare companies
- None.
Senior Biotechnology and Specialty Healthcare Financial Executive Brings Extensive Experience in Leading Acquisition and Organic Growth Initiatives
LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today announced the appointment of Nathen Fuentes, CPA, as Chief Financial Officer effective January 2, 2025, replacing interim CFO Simon Tarsh.
Nathen Fuentes comes to Renovaro as a senior biotechnology and specialty healthcare financial executive with a depth and breadth of functional and industry experiences based upon progressively senior strategic, operational and financial leadership roles. Mr. Fuentes has experience leading acquisition and organic growth initiatives within highly levered environments while managing investor relations, human resources, finance, accounting, and revenue cycle functions. Prior to joining Renovaro he served as Chief Financial Officer at Telomir Pharmaceuticals, an emerging leader in age-reversal science. Previously, Mr. Fuentes worked for mid-market private equity sponsored companies within the specialty healthcare industry, serving as Chief Financial Officer of Emergence Health Holdings, Divergent Dental Group, Family First Homecare and Dermatology Medical Partners. He also served as the Controller of Glytec, as an Experienced Associate at PricewaterhouseCoopers, and held various managerial positions with homebuilding companies prior to his experience with PricewaterhouseCoopers. Mr. Fuentes earned his Bachelor of Science in marketing from the University of Florida and his Master of Science in accounting from Fairfield University. Mr. Fuentes is a Certified Public Accountant.
David Weinstein, Chief Executive Officer of Renovaro, commented, “We welcome Nathen to the position and are honored to have someone of his caliber and financial skill set serve as our CFO. Nathen brings a dedicated work ethic as well as a proven and concentrated experience in the biotechnology and healthcare industries. We believe his experience will be instrumental as we focus on revolutionizing healthcare by combining advanced diagnostic and personalized immunotherapy for early diagnosis, better-targeted treatments, and drug discovery.”
Mr. Fuentes added, “I am excited to be appointed as CFO as we prepare Renovaro to realize its potential to offer cancer patients early diagnosis, a treatment protocol, and recurrence monitoring. I look forward to working with David, the senior leadership team, and our finance team as we continue to execute on our strategic and financial priorities and our commitments to all shareholders.”
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube. For more information visit renovarogroup.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.com and STarsh@Renovarogroup.com
FAQ
When did Nathen Fuentes join Renovaro (RENB) as CFO?
What is Nathen Fuentes' previous experience before joining Renovaro (RENB)?
Who did Nathen Fuentes replace as CFO at Renovaro (RENB)?
What are Nathen Fuentes' educational qualifications for the RENB CFO position?
What is Renovaro's (RENB) main business focus?
